STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice - PubMed (original) (raw)

doi: 10.1136/gut.2005.079343. Epub 2006 May 8.

S Matsumoto, S Rose-John, A Suzuki, T Hara, N Tomiyasu, K Handa, O Tsuruta, H Funabashi, J Scheller, A Toyonaga, M Sata

Affiliations

STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice

K Mitsuyama et al. Gut. 2006 Sep.

Abstract

Background and aims: SAMP1/Yit mice spontaneously develops intestinal inflammation. Previously, we demonstrated that the signal transducer and activator of transcription (STAT)-3/suppressor of cytokine signalling (SOCS)-3 pathway is pivotal in human inflammatory bowel disease. In our studies in SAMP1/Yit mice, the aim was to investigate whether STAT3 activation contributes to ileitis and to examine the therapeutic effects of this signal blockade.

Methods: Intestinal expression of phospho-STAT3 in SAMP1/Yit mice and control AKR/J mice was examined by western blotting and immunohistochemistry. SOCS3 and interleukin 6 (IL-6) mRNA were determined by northern blotting and reverse transcription-polymerase chain reaction, respectively. We also examined the effects of intravenously injected hyper-IL-6, an IL-6/soluble IL-6 receptor fusion protein, and of soluble gp130-Fc, a specific inhibitor of soluble IL-6 receptor signalling, on STAT3 phosphorylation and disease severity in SAMP1/Yit mice.

Results: Phospho-STAT3 was expressed strongly during the disease course in SAMP1/Yit mice but only transiently in AKR/J mice. Phospho-STAT3 was localised to epithelial and mononuclear cells in the diseased intestine of SAMP1/Yit mice. SOCS3 as well as IL-6 mRNAs were expressed in affected intestine. Administration of hyper-IL-6 caused disease exacerbation and enhancement of STAT3 phosphorylation. In contrast, soluble gp130-Fc administration ameliorated the disease and suppressed STAT3 phosphorylation.

Conclusion: STAT3 signalling is critical in the development of intestinal inflammation in SAMP1/Yit mice. Blockade of this signalling pathway by soluble gp130-Fc may have therapeutic effects in inflammatory bowel disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Comment in

Similar articles

Cited by

References

    1. Katz J A, Itoh J, Fiocchi C. Pathogenesis of inflammatory bowel disease. Curr Opin Gastroenterol 199915291–297. - PubMed
    1. Podolsky D K, Fiocchi C. Cytokine, chemokines, growth factors, eicosanoids, and other bioactive molecules in inflammatory bowel disease. In: Kirsner JB, ed. Inflammatory bowel disease, 5th edn. Philadelphia: W B Saunders, 2000191–207.
    1. Sartor R B. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994106533–539. - PubMed
    1. Darnell J E., Jr STATs and gene regulation. Science 19972771630–1635. - PubMed
    1. Fu X Y, Schindler C, Improta T.et al The proteins of ISGF‐3, the interferon alpha‐induced transcriptional activator, define a gene family involved in signal transduction. Proc Natl Acad Sci U S A 1992897840–7843. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources